Metabolomics-based study on the significance of differential metabolite binding IgG isoforms in Hemolytic disease of newborn

References

• Myle AK, Al-Khattabi GH. Hemolytic disease of the newborn: a review of current trends and prospects. Pediatric Health Med Ther. 2021;12:491–498. doi:10.2147/phmt.S327032
   PubMed Web of Science ®Google Scholar
• Jackson ME, Baker JM. Hemolytic disease of the fetus and newborn: historical and current state. Clin Lab Med. 2021;41:133–151. doi:10.1016/j.cll.2020.10.009
   PubMed Web of Science ®Google Scholar
• Dziegiel MH, Krog GR, Hansen AT, et al. Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn. Transfus Med Hemother. 2021;48:306–315. doi:10.1159/000518782
   PubMed Web of Science ®Google Scholar
• Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol. 2001;13:993–1002. doi:10.1093/intimm/13.8.993
   PubMed Web of Science ®Google Scholar
• Borghi S, Bournazos S, Thulin NK, et al. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci USA. 2020;117:12943–12951. doi:10.1073/pnas.2004325117
   PubMed Web of Science ®Google Scholar
• de Winter DP, Kaminski A, Tjoa ML, et al. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth. 2023;23:12, doi:10.1186/s12884-022-05329-z
   PubMed Web of Science ®Google Scholar
• Metcalf RA, Khan J, Andrews J, et al. Severe ABO hemolytic disease of the newborn requiring exchange transfusion. J Pediatr Hematol Oncol. 2019;41:632–634. doi:10.1097/mph.0000000000001248
   PubMed Web of Science ®Google Scholar
• Karanam A, Bandiya P. Hemolytic disease of newborn: beyond Rh-D and ABO incompatibility. Indian Pediatr. 2021;58:794–795.
   PubMed Web of Science ®Google Scholar
• Vardar G, Okan MA, Karadag N, et al. Intravenous immunoglobulin in hemolytic disease of the newborn: a moving target in time. Niger J Clin Pract. 2022;25:1262–1268. doi:10.4103/njcp.njcp_1_22
   PubMed Web of Science ®Google Scholar
• Sun Y, Ma T, Wang WH, et al. Transfusion rates and disease spectrum in neonates treated with blood transfusion in China. Medicine (Baltimore). 2020;99:e19961, doi:10.1097/md.0000000000019961
   PubMed Web of Science ®Google Scholar
• Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015:146–151. doi:10.1182/asheducation-2015.1.146
   PubMedGoogle Scholar
• Sainio S, Nupponen I, Kuosmanen M, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015;94:383–390. doi:10.1111/aogs.12590
   PubMed Web of Science ®Google Scholar
• Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17:451–459. doi:10.1038/nrm.2016.25
   PubMed Web of Science ®Google Scholar
• Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, et al. Untargeted metabolomics strategies-challenges and emerging directions. J Am Soc Mass Spectrom. 2016;27:1897–1905. doi:10.1007/s13361-016-1469-y
   PubMed Web of Science ®Google Scholar
• Guijas C, Montenegro-Burke JR, Warth B, et al. Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol. 2018;36:316–320. doi:10.1038/nbt.4101
   PubMed Web of Science ®Google Scholar
• Filla LA, Edwards JL. Metabolomics in diabetic complications. Mol Biosyst. 2016;12:1090–1105. doi:10.1039/c6mb00014b
   PubMed Web of Science ®Google Scholar
• Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr Protoc Mol Biol. 2016;114:30.34.31–30.34.32. doi:10.1002/0471142727.mb3004s114
   Google Scholar
• Sarwar A, Citla Sridhar D. Rh hemolytic disease. In StatPearls. StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL).2024.
   Google Scholar
• Gulli F, Basile U, Gragnani L, et al. IgG cryoglobulinemia. Eur Rev Med Pharmacol Sci. 2018;22:6057–6062. doi:10.26355/eurrev_201809_15943
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin X, Guan L, et al. IgG4-related disease with gastrointestinal involvement: case reports and literature review. Front Immunol. 2022;13:816830, doi:10.3389/fimmu.2022.816830
   PubMed Web of Science ®Google Scholar
• Tsuda M, Okada H, Kojima N, et al. Cecal patches generate abundant IgG2b-bearing B cells that are reactive to commensal microbiota. J Immunol Res. 2022;2022:3974141, doi:10.1155/2022/3974141
   PubMed Web of Science ®Google Scholar
• Wang F, Tsai JC, Davis JH, et al. Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models. MAbs. 2020;12:1685350, doi:10.1080/19420862.2019.1685350
   PubMed Web of Science ®Google Scholar
• Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28:285–295. doi:10.1016/j.ccell.2015.08.004
   PubMed Web of Science ®Google Scholar
• Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13:45, doi:10.1186/s13045-020-00876-4
   PubMed Web of Science ®Google Scholar
• Páez M, Jiménez M, Corredor A. Hemolytic disease in fetuses and newborns due to antibodies against the M-antigen. Biomedica. 2021;41:643–650. doi:10.7705/biomedica.5930
   PubMedGoogle Scholar
• Yasuda H, Ohto H, Nollet KE, et al. Hemolytic disease of the fetus and newborn with late-onset anemia due to anti-M: a case report and review of the Japanese literature. Transfus Med Rev. 2014;28:1–6. doi:10.1016/j.tmrv.2013.10.002
   PubMed Web of Science ®Google Scholar
• Ishida A, Ohto H, Yasuda H, et al. Anti-M antibody induced prolonged anemia following hemolytic disease of the newborn due to erythropoietic suppression in 2 siblings. J Pediatr Hematol Oncol. 2015;37:e375–e377. doi:10.1097/mph.0000000000000341
   PubMed Web of Science ®Google Scholar
• Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem. 1995;38:4191–4197. doi:10.1021/jm00021a008
   PubMed Web of Science ®Google Scholar
• Hamzawy MA, Abo-Youssef AM, Malak MN, et al. Multiple targets of Nrf 2 inhibitor; TRIGONELLINE in combating urethane-induced lung cancer by caspase-executioner apoptosis, cGMP and limitation of cyclin D1 and Bcl2. Eur Rev Med Pharmacol Sci. 2022;26:9393–9408. doi:10.26355/eurrev_202212_30690
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kimura T, Yamaga T, et al. Prostate cancer cells in different androgen receptor status employ different leucine transporters. Prostate. 2017;77:222–233. doi:10.1002/pros.23263
   PubMed Web of Science ®Google Scholar